Cervical cancer prevention may be entering a more precise phase as researchers investigate microRNAs—tiny regulatory molecules that can reveal how human cells respond to viral infection and malignant transformation—as potential biomarkers for identifying cervical precancer. A study published in the British Journal of Cancer examines whether microRNA signatures in cervical scrape samples can help triage women who test positive for high-risk human papillomavirus, or HPV, the virus responsible for the vast majority of cervical cancer cases.
The research, led by Laura Valentina Mejia Guarnizo, Carlos Eduardo Trujillo Gama and Liliana López Kleine, addresses a central problem in cervical cancer screening. Testing positive for high-risk HPV indicates that a woman carries a viral type associated with an increased risk of cervical intraepithelial neoplasia, the abnormal growth of cells that can precede invasive cancer. Yet most HPV infections are transient and are cleared by the immune system without causing serious disease. A positive HPV result therefore identifies risk, but does not by itself determine whether clinically important precancer is present.
That distinction has become increasingly important as HPV-based screening expands. Compared with conventional cytology, which examines cervical cells for visible abnormalities, molecular HPV tests are highly sensitive. Their sensitivity, however, can lead to additional examinations for women whose infections may never progress. Current triage approaches aim to separate women who require immediate diagnostic evaluation from those who can safely undergo surveillance. The study investigates whether microRNAs could provide an additional biological layer of information for making that decision.
MicroRNAs are short, non-coding RNA molecules, generally around 20 to 24 nucleotides long, that regulate gene activity after transcription. By binding to messenger RNAs, they can prevent the production of particular proteins or promote the degradation of the messages that encode them. A single microRNA can influence multiple cellular pathways, including proliferation, programmed cell death, immune signaling and tissue differentiation. Because these pathways are disrupted during persistent viral infection and cancer development, microRNA patterns may change before structural abnormalities become obvious under microscopic examination.
High-risk HPV can alter cervical cell biology through viral proteins that interfere with key tumor-suppressor systems. The viral proteins E6 and E7 are particularly important: E6 promotes the degradation of p53, a protein involved in DNA-damage responses and apoptosis, while E7 disrupts the retinoblastoma pathway that normally restrains cell-cycle progression. These effects can create genomic instability and uncontrolled proliferation when infection persists. MicroRNAs may reflect the combined consequences of these viral activities, the host immune response and the gradual evolution of precancerous lesions.
The researchers focused on cervical scrape samples, material already collected during routine screening. This approach is significant because it could allow molecular triage to be incorporated into existing clinical workflows without requiring an entirely new form of specimen collection. Cells and extracellular material recovered from a cervical sample may contain measurable microRNAs, which can be analyzed using molecular techniques designed to quantify their abundance. In principle, a pattern of increased or decreased microRNA expression could distinguish HPV-positive women with cervical intraepithelial neoplasia from those without clinically meaningful lesions.
The study’s contribution lies in examining microRNAs as biomarkers specifically within the difficult group of women who are already known to carry high-risk HPV. The key clinical question is not simply whether a woman is infected, but whether the infection is associated with cellular changes that warrant colposcopy, biopsy or closer follow-up. A reliable microRNA-based test could make this second decision more biologically informed. It might reduce unnecessary referrals while helping identify lesions that could otherwise be missed by less specific triage methods.
Any biomarker intended for screening must meet demanding standards before it can be used routinely. Researchers must establish how consistently the microRNA signals can be measured, whether the results remain stable across laboratories and sampling conditions, and how accurately they classify different grades of cervical intraepithelial neoplasia. Performance is usually assessed through measures such as sensitivity, specificity and the area under the receiver operating characteristic curve. Clinical usefulness also depends on whether a test improves outcomes in diverse populations, including women of different ages, ethnic backgrounds and screening histories.
MicroRNA testing could eventually complement, rather than replace, HPV detection and cytological assessment. HPV testing identifies the presence of a potentially dangerous viral infection, while microRNA profiles may indicate the biological consequences of that infection in cervical tissue. Combining these signals could support a risk-based system in which women receive management according to the probability of significant disease rather than a positive result alone. The approach is particularly relevant in settings where specialist colposcopy services are limited and unnecessary referrals place pressure on already stretched health systems.
The findings reported by Mejia Guarnizo and colleagues add to a growing effort to translate molecular knowledge of HPV-driven disease into practical screening tools. Their work positions microRNAs as possible intermediaries between virology and clinical diagnosis: molecules small enough to be measured in routine samples, yet informative about large-scale changes in cellular regulation. Further validation will determine whether the identified biomarkers can deliver dependable triage in real-world screening programmes. If they do, cervical scrape samples could provide not only evidence of viral exposure, but also a molecular snapshot of whether HPV is beginning to reshape the biology of the cervix in a way that demands intervention.
Subject of Research: MicroRNAs as biomarkers for triage of cervical intraepithelial neoplasia in high-risk HPV-positive women.
Article Title: Identification of microRNAs as biomarkers for triage of cervical intraepithelial neoplasia in cervical scrape samples from high-risk HPV-positive women.
Article References: Mejia Guarnizo, L.V., Trujillo Gama, C.E., López Kleine, L. et al. “Identification of microRNAs as biomarkers for triage of cervical intraepithelial neoplasia in cervical scrape samples from high-risk HPV-positive women.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03521-y
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03521-y
Keywords: high-risk HPV, cervical cancer, cervical intraepithelial neoplasia, microRNAs, biomarkers, cervical screening, molecular triage, viral infection, precision medicine
Tags: advances in cervical cancer diagnosticscervical scrape sample analysis for microRNA biomarkersearly detection of cervical intraepithelial neoplasiahigh-risk HPV infection and cervical lesion risk assessmentHPV-positive women cervical cancer screeningmicroRNA biomarkers for cervical lesion triagemicroRNA roles in HPV-related cervical cancermicroRNA-based risk stratificationmolecular signatures for cervical precancer detectionmolecular triage methods for HPV-positive womennon-invasive cervical cancer biomarkersprecision in cervical cancer screening using microRNAs
